His oncologic history began in [**2197-8-10**] when a torso CT performed due to dyspnea was noted to have large right renal mass and multiple lung nodules.
PET CT on [**2199-3-11**] showed multiple pulmonary nodules and mildly prominent mesenteric nodes.
Followup torso CT [**2199-6-10**] revealed stable lung nodules but a new pancreatic mass.
He passed eligibility testing and began cycle 1 week 1 high-dose IL-2 on [**2199-7-1**] receiving 11 of 14 doses.
VITAL SIGNS:  97.9, 92, 20, 112/64, O2 sat 98% on room air.
ADMISSION LABS:  WBC 5.7, hemoglobin 14.3, hematocrit 41.6, platelet count 453,000.
INR 1.1.
BUN 18, creatinine 1.6.
Sodium 138, potassium 4.9, chloride 106, CO2 of 22.
ALT 36, AST 26.
CK 30.
His admission weight was 97 kg and he received Interleukin-2, 600,000 international units per kilo equaling 49.7 million units based on adjusted ideal body weight.
On treatment day number 4, he was noted to be become hypotensive to systolic blood pressure of mid 80s without response to fluid boluses.
While on dopamine, he was noted to go into rapid atrial fibrillation with a heart rate between 160 and 180.
He was subsequently placed on amiodarone with improvement in his heart rate and eventual conversion to normal sinus rhythm.
IL-2 therapy was held at that time and blood pressure remained stable throughout the rest of his hospitalization.
During this week he developed acute renal failure with a peak creatinine of 4.4 with associated oliguria.
Metabolic acidosis was noted with a minimum bicarb of 12 and improved with bicarb repletion up to 19.
He developed hyperbilirubinemia with a peak bilirubin of 3.3, improved to 3.2 at the time of discharge.
He developed thrombocytopenia with a platelet count low 75,000 without evidence of bleeding.
FOLLOWUP:  The patient will return to clinic in 4 weeks after CT scans to assess disease response.
